A supplement of meso-zeaxanthin may bolster macular pigment optical density (MPOD), according to researchers from Florida International University (Nutr Metab . 2007;4:12) (DOI:10.1186/1743-7075-4-12). Lutein and zeaxanthin have been the primary focus of research trials exploring how the xanthophyll carotenoids can support macular pigment and possibly prevent onset of age-related macular degeneration (AMD). Meso-zeaxanthin is the third major carotenoid found in macular pigment.
Update on Meso-Zeaxanthin
A new study, known as Meso-zeaxanthin ocular supplementation trial (MOST), begins in late March 2010 and the clinical research team are currently recruiting suitable candidates. The specialists involved in the trial are research experts in this area of eye disease. The trial requires 60 patients who have been diagnosed with early AMD. After a complimentary eye screening by an IVR Ophthalmologist, suitable candidates will be enrolled into the trial and provided with a 12-month course of dietary supplements containing the macular pigments.
For further information on AMD or on the MOST trial being conducted at the Institute of Vision Research, please contact: Eithne Connolly, Clinical Research Technician, on 051 302153 or at eithneativr.ie
Editor’s Note: Recent studies have shown that the carotenoid mesozeaxanthin, in the family of lutein and zeaxanthin, is used as an antioxidant directly in the center of the retina. Hopefully this study will further confirm that this nutrient along with a family of other essential nutrients helps preserve vision for those with macular degeneration.